586 related articles for article (PubMed ID: 23896421)
1. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
[TBL] [Abstract][Full Text] [Related]
3. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
5. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
9. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.
Mahadevia PJ; Masaquel AS; Polak MJ; Weiner LB
J Med Econ; 2012; 15(5):987-96. PubMed ID: 22574798
[TBL] [Abstract][Full Text] [Related]
10. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
14. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
16. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
Paes B; Steele S; Janes M; Pinelli J
Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
18. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
[TBL] [Abstract][Full Text] [Related]
19. A review of cost-effectiveness of palivizumab for respiratory syncytial virus.
Hussman JM; Li A; Paes B; Lanctôt KL
Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):553-67. PubMed ID: 23140255
[TBL] [Abstract][Full Text] [Related]
20. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
